20150629 PR 29 juin fin
Category: dates
Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)
20150601 PR TG4010 TIME results_ASCO 2015_FINAL
Results of the Phase 2B Part of Time Study Evaluating TG4010 Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy
Elisabeth Quoix, et al. ASCO Annual Meeting 2015 – May 29-June 2, 2015 – Chicago, Illinois Download the poster here Poster Presentation
Transgene Announces Participation at Upcoming Investor Events
20150518 May thru July 2015 IR events_ver 1 ENG
TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models
Karine Lélu, et al. Journal of Hepatology, April 2015, Volume 62, Supplement 2, Page S205 – Download the article Publication
TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models
Karine Lélu, et al. EASL Liver Congress 2015, Vienna-23th April 2015 Download the poster here Poster Presentation
Transgene Presents New Data with TG1050, an Immunotherapy being Developed to Treat Chronic Hepatitis B, at The International Liver Congress™ 2015
20150423 – US – EASL2015 TG1050
Transgene Reports First Quarter 2015 Financial Results
20150422 PR US Q1 2015
Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody
20150421 AACR 2015_English
Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer
Poster TG4010-AACR 2015-KR Karola Rittner, et al. AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2497 Download the posterhere Poster Presentation